AspyreRx is on showcase at the Advanced Technologies & Treatments for Diabetes (ATTD) 2024 meeting in Florence, Italy. Our Medical Director Kara Mosesso, ANP-BC is hosting a symposium on Saturday and Nicole Guthrie is at the booth talking with #healthcareproviders about the power of behavior change in treating #type2diabetes ??
Better Therapeutics
生物技术研究
San Francisco,CA 10,735 位关注者
We believe software can treat disease by changing the behaviors that cause it #digitaltherapeutics #dtx
关于我们
Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better went public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the fall of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies. Better Therapeutics operates as a fully distributed company combining remote work with periodic team and all-hands in-person meetings. We are headquartered in San Francisco, CA and have employees located in 18 states across the country. For more information, please visit our website at www.bettertx.com
- 网站
-
https://www.bettertx.com
Better Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- San Francisco,CA
- 类型
- 上市公司
- 创立
- 2015
- 领域
- digital therapeutics、lifestyle medicine、neuroscience、behavioral psychology、disease reversal、digital health、chronic disease、diabetes、heart disease、cognitive behavioral therapy、behavioral science、cardiometabolic conditions、type 2 diabetes、hyperlipidemia、research and development、prescription digital therapeutics、hypertension和prescription software
地点
-
主要
US,CA,San Francisco
Better Therapeutics员工
-
Lindsey Reinford, NBC-HWC
Content Manager | Health and Development Writer | Human Venn diagram of connection, compassion, and creativity
-
David Perry
Chairman and Co-founder of Better Therapeutics
-
Laura Madu M.A, NBC-HWC (she/her/hers)
Health Coach | Mentor & Trainer | Innovator in Digital Health
-
Kate Edwards, FNP-C
Culinary Medicine Lead at Better Therapeutics
动态
-
?? Breaking News Alert! ?? We're excited to announce our partnership with the American College of Lifestyle Medicine to enhance access to innovative #diabetes treatments for patients in underserved communities disproportionately impacted by type 2 diabetes. Together, we're committed to providing one million prescriptions ?? for AspyreRx available through 1,400 Federally Qualified Health Center (FQHC) organizations. Software-based treatments like AspyreRx have the potential to help address healthcare disparities in significant ways by ensuring that everyone has access to the care they need. Read more ?? https://lnkd.in/gxADu63n #HealthcareForAll #CommunityHealth #Type2DiabetesAwareness #DTx #digitaltherapeutics
-
-
Businesses often thrive by forming strong partnerships, and we are excited to reach more #healthcare providers and patients through our partnership with Glooko. Briana Thompson is spearheading this effort and shared insights today at #DTxWest in LA. Thanks David A Conn for sharing the stage.
David A Conn and Briana Thompson teach us how Glooko and Better Therapeutics met at DTx East and built a partnership. #DTxWest #digitaltherapeutics
-
-
Naim Alkhouri, PI for the LivVita Liver Study, shares his excitement for securing Breakthrough status for our novel #cognitivebehavioraltherapy device to offer a potential solutions for the millions of patients with advanced liver disease. Thank you Naim and Mazen Noureddin, MD, MHSc, who served as Senior Scientific Advisor for the study, for the clinical expertise, dedication to patients and support these past years. #innovationinhealthcare #digitalhealth #dtx
-
-
There are currently no FDA approved drugs or devices for patients with advanced liver disease. Today we get one step closer with breakthrough device designation for our novel #cognitivebehavioraltherapy device. Our CEO Frank Karbe shares how this signifies the FDA's recognition of this potential treatment option.
-
-
#news We have secured Breakthrough Designation from the #FDA for our novel Cognitive Behavioral Therapeutic device as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH) Read more ?? https://lnkd.in/gB8w-Thz
-
-
#news In a step towards securing broad coverage for AspyreRx, we are thrilled to announce a rebate agreement with one of the top 3 PBMs in the US. https://lnkd.in/gFC7Dru4
-
Kicking off 2024 with our first national sales meeting! Christian Meyer, MBA has built an incredible team of talented people, and bringing everyone together has been energizing. The prevalence and cost burden of #diabetes continue to escalate and we are inspired to make a difference with #AspyreRx. #healthcareinnovation #digitaltreatment Denise Capo, Briana Thompson, David Perry, Frank Karbe, Aaron Bemister, Kristin Wynholds, Jessica Meng, John Eitzen, Brian Carroll, Mark Berman, MD, Emma (Reynolds) Williams with Catherine Hoy and Michael Carothers, MBA joining remotely due to travel disruptions!
-
-
Following the #news last week of our partnership with Glooko, our CEO Frank Karbe spoke with Vator about the vision we have, and the potential of this integration with the Glooko platform. https://lnkd.in/g-T5ZsDZ
Better Therapeutics CEO talks partnership with Glooko
vator.tv
-
We are thrilled to share the #partnership #news announced today with Glooko. This collaboration will enable healthcare providers in the United States who use the Glooko platform to identify suitable patients for AspyreRx, facilitate prescriptions, and track patients throughout their treatment. Read the press release ?? https://lnkd.in/gXm5m-zg
-